TTrialPathMatch Me to Trials
← Back to trials
RecruitingProstate Cancer Metastatic

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Eligible age

18+ yrs

Accepts

All genders

Locations

27 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) in participants with mCRPC previously treated with next-generation hormonal agent (NHA) and taxane-based chemotherapy. It is hypothesized that opevesostat is superior with respect to OS in androgen receptor ligand binding domain (AR LBD) mutation-negative and -positive participants.

Sponsor: Merck Sharp & Dohme LLC

You may qualify if…

  • ✓ Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology.
  • ✓ Has prostate cancer progression while on androgen deprivation therapy (or post bilateral orchiectomy) within 6 months before Screening
  • ✓ Has current evidence of distant metastatic disease (M1 disease) documented by either bone lesions on bone scan and/or soft tissue disease by computed tomography/magnetic resonance imaging (CT/MRI).
  • ✓ Has disease that progressed during or after treatment with 1 novel hormonal agent (NHA)
  • ✓ Has received 1 but no more than 2 taxane-based chemotherapy regimens for metastatic castration-resistant prostate cancer (mCRPC) and has had progressive disease (PD) during or after treatment
  • ✓ Has ongoing androgen deprivation with serum testosterone \<50 ng/dL (\<1.7 nM)
  • ✓ Has provided tumor tissue from a fresh core or excisional biopsy from soft tissue not previously irradiated
  • ✓ Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days of randomization

You may not qualify if…

  • ✕ Has a gastrointestinal disorder that might affect absorption
  • ✕ Has a history of pituitary dysfunction
  • ✕ Has poorly controlled diabetes mellitus
  • ✕ Has clinically significant abnormal serum potassium or sodium level
  • ✕ Has a history of active or unstable cardio/cerebro-vascular disease, including thromboembolic events
  • ✕ Has a history of seizure within 6 months of providing documented informed consent or any condition that may predispose to seizures within 12 months before the date of randomization
  • ✕ Has a history of clinically significant ventricular arrhythmias
  • ✕ Has received an anticancer monoclonal antibody (mAb) within 4 weeks before the date of randomization, or has not recovered from adverse events (AEs) due to mAbs administered more than 4 weeks before the date of randomization

Where it's recruiting

California

Orange · Palo Alto · Riverside

Colorado

Aurora · Highlands Ranch · Lakewood · Lone Tree

Connecticut

New Haven

Florida

Fort Myers · Miami

Illinois

Chicago

Iowa

Iowa City

Kentucky

Lexington

Louisiana

New Orleans

Maryland

Baltimore

Michigan

Detroit

Minnesota

Marshall · Minneapolis · Saint Louis Park

Mississippi

Hattiesburg

Source: ClinicalTrials.gov · NCT06136624 · last updated 2026-11-13

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-568 · TrialPath